Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMD14 | O00487 | 3/20 | 0.62 |
| ▸ | COPS5 | Q92905 | 3/20 | 0.62 |
| ▸ | CCR1 | P32246 | 4/20 | 0.53 |
| ▸ | CCR8 | P51685 | 4/20 | 0.53 |
| ▸ | CCR5 | P51681 | 2/20 | 0.53 |
| ▸ | SLC40A1 | Q9NP59 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21788159 | 0.84 | PSMD14 (0.59) | PSMD14COPS5CCR1CCR8CCR5 | |
| SCHEMBL22270813 | 0.82 | SLC40A1 (0.48) | PSMD14COPS5CCR1CCR8CCR5 | |
| SCHEMBL21893494 | 0.80 | PSMD14 (0.46) | PSMD14COPS5CCR1CCR8CCR5 | |
| SCHEMBL24654874 | 0.80 | PTPN6 (0.43) | PSMD14COPS5CCR1CCR8CCR5 | |
| SCHEMBL2569765 | 0.80 | PSMD14 (0.55) | PSMD14COPS5CCR1CCR8CCR5 | |
| SCHEMBL29935933 | 0.80 | PSMD14 (0.55) | PSMD14COPS5CCR1CCR8CCR5 | |
| SCHEMBL2942804 | 0.79 | KDM4E (0.44) | PSMD14COPS5CCR1CCR8CCR5 | |
| SCHEMBL29862565 | 0.79 | PSMD14 (0.41) | PSMD14COPS5CCR1CCR8CCR5 | |
| SCHEMBL20392639 | 0.79 | PSMD14 (0.41) | PSMD14COPS5CCR1CCR8CCR5 | |
| SCHEMBL23717029 | 0.79 | PSMD14 (0.41) | PSMD14COPS5CCR1CCR8CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3686199-B9 | FUSED RING DERIVATIVE AS A2A RECEPTOR INHIBITOR | CSTONE PHARMACEUTICALS SUZHOU CO LTD (CN) | 2022-12-07 | — | — | EP | disclosed |
| EP-3686199-A1 | FUSED RING DERIVATIVE AS A2A RECEPTOR INHIBITOR | CSTONE PHARMACEUTICALS (SUZHOU) CO., LTD. (CN) | 2020-07-29 | — | — | EP | disclosed |
| WO-2020065613-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | WO | disclosed |
| EP-2149574-B1 | 2, 6-DINITROGEN-CONTAINING SUBSTITUTED PURINE DERIVATIVES, THE PREPARATION AND USES THEREOF | ZHEJIANG MED XINCHANG PHARM (CN) | 2015-12-02 | — | — | EP | disclosed |
| US-8580763-B2 | 2, 6-dinitrogen-containing substituted purine derivatives, the preparation and uses thereof | ZHANGGUI WU (CN) | 2013-11-12 | — | — | US | disclosed |
| US-8580763-B2 | 2, 6-dinitrogen-containing substituted purine derivatives, the preparation and uses thereof | ZHANGGUI WU (CN) | 2013-11-12 | — | — | US | disclosed |
| US-20100144663-A1 | 2, 6-Dinitrogen-Containing Substituted Purine Derivatives, The Preparation And Uses Thereof | ZHE JIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) | 2010-06-10 | — | — | US | disclosed |
| US-20100144663-A1 | 2, 6-Dinitrogen-Containing Substituted Purine Derivatives, The Preparation And Uses Thereof | ZHE JIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) | 2010-06-10 | — | — | US | disclosed |
| EP-2149574-A1 | 2, 6-DINITROGEN-CONTAINING SUBSTITUTED PURINE DERIVATIVES, THE PREPARATION AND USES THEREOF | ZheJiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory (CN) | 2010-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144663-A1 | 2, 6-Dinitrogen-Containing Substituted Purine Derivatives, The Preparation And Uses Thereof | PNP, NUDT1, DPYD | PSMD14 4223/4885COPS5 2993/4885CCR1 3929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.